EN PL
ORIGINAL PAPER
Symptom-modifying effects of oral avocado/soybean unsaponifiables in routine treatment of knee osteoarthritis in Poland. An open, prospective observational study of patients adherent to a 6-month treatment
 
More details
Hide details
 
Submission date: 2016-10-14
 
 
Final revision date: 2016-10-29
 
 
Acceptance date: 2016-10-30
 
 
Online publication date: 2016-11-28
 
 
Publication date: 2016-10-28
 
 
Reumatologia 2016;54(5):217-226
 
KEYWORDS
TOPICS
ABSTRACT
Objectives: Observational studies provide insights into real-life situations. Therefore, we assessed the effects of oral avocado/soybean unsaponifiable (ASU) capsules on pain relief and functional ability in patients, while they were receiving a routine treatment for knee osteoarthritis (OA).
Material and methods: An open, prospective, observational 6-month study was conducted in 99 centers in Poland in a group of 4822 patients with symptomatic knee OA receiving one 300 mg ASU capsule/day as a routine medication. The patients had no diagnoses of other rheumatic diseases and were not treated with other symptomatic slow-acting drugs for osteoarthritis (SYSADOAs). Data on OA symptoms and therapy were collected from the initiation of ASU treatment (visit 0) and during 3 consecutive control visits performed every 2 months (visits 1–3). Functional Lequesne index, severity of joint pain of one symptomatic knee (Laitinen index and VAS), use of analgesics and non-steroidal anti-inflammatory drugs (NSAIDs), adherence to treatment and adverse events were evaluated and recorded using electronic Case Report Forms.
Results: Four thousand one hundred and eighty-six patients (86.8%) attended all 4 visits. In 94.2% of patients (mean age 60.7 ±11.6 years SD, 73.4% female) at least one OA risk factor was identified. There was a significant improvement in functional ability between the last and baseline visits as evidenced by the median Lequesne index decreasing from 8 to 4 points (p < 0.001). Measures of pain intensity also fell significantly (p < 0.001) throughout the study: median Laitinen score decreased from 6 to 3 points, median pain at rest VAS – from 1.8 to 0 cm and median pain during walking VAS – from 5.6 to 1.9 cm. The significant differences were also noted between consecutive visits. The proportion of patients using analgesics and NSAIDs declined from 58.8% at the baseline visit to 24.9% at the last visit 3 (p < 0.001). Defined daily dose of NSAIDs decreased significantly from 1 at the baseline visit to 0.67 at the visit 3. Severe adverse events associated with ASU treatment were not observed.
Conclusions: It was the first observational study in Poland evaluating the effects of routine knee OA treatment with oral ASU. Only a small group of patients (13.2%) treated with ASU discontinued the study. The majority of patients adherent to the ASU treatment for 6 months showed gradual alleviation of joint pain, improvement in functional ability and a significant reduction in NSAIDs intake.
 
REFERENCES (27)
1.
Cross M, Smith E, Hoy D, et al. The global burden of hip and knee osteoarthritis: estimates from the the global burden of disease 2010 study. Ann Rheum Dis 2014; 73: 1323-1330.
 
2.
Bruyère O, Cooper C, Pelletier JP, et al. An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: A report from a task force of the European Society for Clinical and Economic Aspects of Osteo-.
 
3.
porosis and Osteoarthritis (ESCEO). Semin Arthritis Rheum 2014; 44: 253-263.
 
4.
McAlindon TE, Bannuru RR, Sullivan MC, et al. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthritis Cartilage 2014; 22: 363-388.
 
5.
Klimiuk PA, Kuryliszyn-Moskal A. Osteoarthritis. (Aktualizacja zaleceń postępowania diagnostyczno-terapeutycznego w chorobach reumatycznych na podstawie rekomendacji EULAR/ACR). Reumatologia 2016; suppl. 1: 111-113.
 
6.
Fransen M, Agaliotis M, Nairn L, et al. Glucosamine and chondroitin for knee osteoarthritis: a double-blind randomised placebo-controlled clinical trial evaluating single and combination regimes. Ann Rheum Dis 2015; 74: 851-858.
 
7.
Appelboom T, Scheurmans J, Verbruggen G, et al. Symptoms modifying effect of avocado/soybean unsaponifiables (ASU) in knee osteoarthritis. Scand J Rheumatol 2001; 30: 242-247.
 
8.
American Academy of Orthopaedic Surgeons. Treatment of osteoarthritis of the knee. Evidence-based guideline. 2013, 2nd edition. Available at: www. aaos.org.
 
9.
Głuszko P, Bielińska A. Non-steroidal anti-inflammatory drugs and the risk of cardiovascular diseases. Are we going to see the revival of cyclooxygenase-2 selective inhibitors? Pol Arch Med Wewn 2009; 119: 231-235.
 
10.
Maheu E, Cadet C, Marty M, et al. Randomised, controlled trial of avocado-soybean unsaponifiable (piascledine) effects on structure modification in hip osteoarthritis: the ERADIAS study. Ann Rheum Dis 2014; 73: 376-384.
 
11.
HenrotinY E, Sanchez C, Deberg MA, et al. Avocado-soybean unsaponifiables increase aggrecan synthesis and reduce catabolic and proinflammatory mediator production by human osteoarthritic chondrocytes. J Rheumatol 2003; 30: 1825-1834.
 
12.
Boumèdiene K, Felisaz N, Bogdanowicz P, et al. Avocado/soybean unsaponifiables enhance the expression of transforming growth factor b1 and b2 in cultured articular chondrocytes. Arthritis Rheum 1999; 42: 148-156.
 
13.
Henrotin Y, Labasse A, Jaspar J, et al. Effects of three avocado/soybean nsaponifiables mixtures on metalloproteinases, cytokines and prostaglandin E2 production by human articular chondrocytes. Clin Rheumatol 1998; 17: 31-39.
 
14.
Maheu E, Mazières B, Valat JP, et al. Symptomatic efficacy of avocado/soybean unsaponifiables in the treatment of osteoarthritis of the knee and hip: a prospective, randomized, double-blind, placebo-controlled, multicenter clinical trial with a six-month treatment period and a two-month followup demonstrating a persistent effect. Arthritis Rheum 1998; 41: 81-91.
 
15.
Christiansen R, Bartels EM, Astrup A, et al. Symptomatic efficacy of avocado-soybean unsaponifiables (ASU) in osteoarthritis (OA) patients: a meta-analysis of randomized controlled trials. Osteoarthritis Cartilage 2008; 16: 399-408.
 
16.
Blotman F, Maheu E, Wulwik A et al. Efficacy and safety of avocado-soybean unsaponifiables in the treatment of symptomatic osteoarthritis of the knee and hip. A prospective, multicenter, three-month, randomized, duble blind, placebo-controlled trial. Rev Rheum 1997; 64: 825-834.
 
17.
Altman R, Asch E, Bloch D. et al. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the knee. Arthritis Rheum 1986; 29: 1039-1049.
 
18.
Lequesne MG, Mery C, Samson P, et al. Indexes of severity for osteoarthritis of the hip and knee. Scand J Rheumatol Suppl 1987; 65: 85-89.
 
19.
Chariusz M, Gasztych J, Irzmanski R, et al. Comparative analysis of analgesic efficacy of selected physiotherapy methods in low back pain patients. Ortopedia Traumatologia Rehabilitacja 2010; 12: 225-236.
 
20.
Roche N, Reddel H, Martin R, et al. Quality standards for realworld research. Focus on observational database studies of comparative effectiveness. Ann Am Thorac Soc 2014; 11: suppl.
 
21.
2: S99-S104.
 
22.
Reginster J-Y, Reiter-Niesert S, Bruyère F, et al. Recommendation for an update of the current (2010) European Regulatory Guideline on Clinical Investigation of Medicinal Products Used in the Treatment of Osteoarthritis and reflections about related clinically relevant outcomes. Osteoporosis Int 2015; suppl. 1: SE 5.
 
23.
Kienle G, Kiene H. The powerful placebo effect: Fact or fiction. J Clin Epidemiol 1997; 50: 1311-1318.
 
24.
de Craen AJM, Kaptchuk TJ, Tijssen JG, et al. Placebos and placebo effects in medicine: historical overview. J R Soc Med 1999; 92: 511-515.
 
25.
Whitney CW, Von Korff M. Regression to the mean in treated versus untreated chronic pain. Pain 1992; 50: 281-285.
 
26.
Hróbjartsson A, Gotzsche PC. Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment. N Engl J Med 2001; 344: 1594-1602.
 
27.
Atukorala I, Makovey J, Lawler L, et al. Is there a dose-response relationship between weight loss and symptom improvement in persons with knee osteoarthritis? Arthritis Care Res 2016; 68: 1106-1114.
 
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
eISSN:2084-9834
ISSN:0034-6233
Journals System - logo
Scroll to top